263 related articles for article (PubMed ID: 36400886)
41. Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin.
Schneider MA; Eden J; Pache B; Laminger F; Lopez-Lopez V; Steffen T; Hübner M; Kober F; Roka S; Campos PC; Roth L; Gupta A; Siebenhüner A; Kepenekian V; Passot G; Gertsch P; Glehen O; Lehmann K
Ann Surg; 2018 Nov; 268(5):845-853. PubMed ID: 30303876
[TBL] [Abstract][Full Text] [Related]
42. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
[TBL] [Abstract][Full Text] [Related]
43. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez A; Rodriguez-Ortiz L; Baratti D; Schneider MA; Gutiérrez-Calvo A; García-Fadrique A; Tuynman JB; Cascales-Campos PA; Martín VC; Morales R; Salti GI; Arteaga X; Pacheco D; Alonso-Gomez J; Yalkin O; Villarejo-Campos P; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Rufian-Peña S; Briceño J
Ann Surg Oncol; 2019 Aug; 26(8):2595-2604. PubMed ID: 31111351
[TBL] [Abstract][Full Text] [Related]
44. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies.
Flood M; Narasimhan V; Waters P; Ramsay R; Michael M; Warrier S; Heriot A
Surgeon; 2021 Oct; 19(5):310-320. PubMed ID: 33023847
[TBL] [Abstract][Full Text] [Related]
45. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
46. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.
Sun T; Li K; Xu G; Zhu K; Wang Q; Dang C; Yuan D
World J Surg Oncol; 2021 Jul; 19(1):200. PubMed ID: 34229721
[TBL] [Abstract][Full Text] [Related]
47. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study.
Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G
World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826
[TBL] [Abstract][Full Text] [Related]
48. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis.
Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH
Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748
[TBL] [Abstract][Full Text] [Related]
49. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
50. Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity-Score Analysis.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
Ann Surg Oncol; 2024 Jan; 31(1):594-604. PubMed ID: 37831280
[TBL] [Abstract][Full Text] [Related]
51. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3418-3419. PubMed ID: 34743279
[No Abstract] [Full Text] [Related]
52. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Yildirim Y; Sokmen S; Cevlik AD; Bisgin T; Manoglu B; Obuz F
Langenbecks Arch Surg; 2023 May; 408(1):182. PubMed ID: 37148400
[TBL] [Abstract][Full Text] [Related]
55. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Dietz MV; Hannink G; Said I; van der Zant FA; van de Vlasakker VCJ; Brandt-Kerkhof ARM; Verhoef C; Bremers AJA; de Wilt JHW; Hemmer PHJ; de Hingh IHJT; de Reuver PR; Madsen EVE
Eur J Surg Oncol; 2024 Jun; 50(6):108294. PubMed ID: 38583215
[TBL] [Abstract][Full Text] [Related]
56. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
[TBL] [Abstract][Full Text] [Related]
57. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis.
Cho CY; Veerapong J; Baumgartner JM; Murphy JD; Lowy AM; Kelly KJ
Surg Endosc; 2023 Jul; 37(7):5644-5651. PubMed ID: 36477643
[TBL] [Abstract][Full Text] [Related]
58. Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy with and without Diaphragmatic Resection in Patients with Peritoneal Metastases.
Nikiforchin A; Gushchin V; Sittig M; Baron E; Lopez-Ramirez F; Nieroda C; Sardi A
Ann Surg Oncol; 2022 Feb; 29(2):873-882. PubMed ID: 34546479
[TBL] [Abstract][Full Text] [Related]
59. Repeat Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Recurrences is Safe and Efficacious.
Laks S; Schtrechman G; Adileh M; Ben-Yaacov A; Purim O; Ivanov V; Aderka D; Shacham-Shmueli E; Halpern N; Goren S; Perelson D; Nissan A
Ann Surg Oncol; 2021 Sep; 28(9):5330-5338. PubMed ID: 33591479
[TBL] [Abstract][Full Text] [Related]
60. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
